|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.770 USD | +1.39% |
|
+6.56% | -24.59% |
| 14/05 | CorMedix Inc., Q1 2026 Earnings Call, May 14, 2026 | |
| 14/05 | CorMedix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -31.12 | -29.22 | -42.47 | -13.91 | 21.21 | |||||
Return on Total Capital | -33.77 | -32.01 | -48.31 | -17.92 | 31.35 | |||||
Return On Equity % | -52.72 | -50.4 | -74.02 | -23.17 | 66.56 | |||||
Return on Common Equity | -52.72 | -50.4 | -74.02 | -23.17 | 66.15 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 22 | 94.29 | - | 92.66 | 92.91 | |||||
SG&A Margin | 8.56T | 30.59T | - | 135.02 | 30.82 | |||||
EBITDA Margin % | -15.39T | -46.69T | - | -50.71 | 56.11 | |||||
EBITA Margin % | -15.42T | -46.82T | - | -51.07 | 55.89 | |||||
EBIT Margin % | -15.42T | -46.82T | - | -51.43 | 51.44 | |||||
Income From Continuing Operations Margin % | -14.77T | -45.41T | - | -41.24 | 52.31 | |||||
Net Income Margin % | -14.77T | -45.41T | - | -41.24 | 52.31 | |||||
Net Avail. For Common Margin % | -14.77T | -45.41T | - | -41.24 | 51.99 | |||||
Normalized Net Income Margin | -9.64T | -28.94T | - | -27.78 | 32.35 | |||||
Levered Free Cash Flow Margin | -6.67T | -21.44T | - | -102.87 | 34.81 | |||||
Unlevered Free Cash Flow Margin | -6.66T | -21.42T | - | -102.81 | 35.24 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0 | 0 | - | 0.43 | 0.66 | |||||
Fixed Assets Turnover | 0.11 | 0.03 | - | 18.01 | 50.9 | |||||
Receivables Turnover (Average Receivables) | 7.84 | - | - | - | 2.8 | |||||
Inventory Turnover (Average Inventory) | 2.03 | - | - | 0.66 | 1.18 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 12.44 | 9.44 | 6.97 | 3.39 | 2.11 | |||||
Quick Ratio | 12.26 | 9.32 | 6.67 | 3.05 | 1.83 | |||||
Operating Cash Flow to Current Liabilities | -3.96 | -3.86 | -3.37 | -1.5 | 1 | |||||
Days Sales Outstanding (Average Receivables) | 46.57 | - | - | - | 130.5 | |||||
Days Outstanding Inventory (Average Inventory) | 179.6 | - | - | 556.7 | 308.31 | |||||
Average Days Payable Outstanding | 72.67T | - | - | 126.44 | 39.65 | |||||
Cash Conversion Cycle (Average Days) | -72.44T | - | - | - | 399.15 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 1.47 | 1.46 | 0.95 | 0.61 | 36.74 | |||||
Total Debt / Total Capital | 1.45 | 1.44 | 0.94 | 0.61 | 26.87 | |||||
LT Debt/Equity | 1.28 | 1.21 | 0.74 | 0.41 | 36.38 | |||||
Long-Term Debt / Total Capital | 1.26 | 1.2 | 0.73 | 0.41 | 26.61 | |||||
Total Liabilities / Total Assets | 8.92 | 11.25 | 14.52 | 28.77 | 50.94 | |||||
EBIT / Interest Expense | -1.85T | -1.15T | -1.43T | -614.1 | 57.64 | |||||
EBITDA / Interest Expense | -1.83T | -1.14T | -1.42T | -599.99 | 62.96 | |||||
(EBITDA - Capex) / Interest Expense | -1.92T | -1.15T | -1.43T | -603.17 | 62.15 | |||||
Total Debt / EBITDA | -0.03 | -0.03 | -0.01 | -0.02 | 0.85 | |||||
Net Debt / EBITDA | 2.21 | 1.91 | 1.55 | 2.34 | -0.06 | |||||
Total Debt / (EBITDA - Capex) | -0.03 | -0.03 | -0.01 | -0.02 | 0.86 | |||||
Net Debt / (EBITDA - Capex) | 2.11 | 1.9 | 1.54 | 2.33 | -0.06 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -20.19 | -65.74 | - | - | 617.03 | |||||
Gross Profit, 1 Yr. Growth % | 22.14 | 46.85 | - | - | 616.21 | |||||
EBITDA, 1 Yr. Growth % | 8.43 | 3.96 | 60.08 | -54.9 | -893.3 | |||||
EBITA, 1 Yr. Growth % | 8.14 | 4.03 | 59.87 | -54.65 | -884.74 | |||||
EBIT, 1 Yr. Growth % | 8.14 | 4.03 | 59.87 | -54.34 | -817.22 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 28.07 | 5.29 | 56.02 | -61.31 | -1.01T | |||||
Net Income, 1 Yr. Growth % | 28.07 | 5.29 | 56.02 | -61.31 | -1.01T | |||||
Normalized Net Income, 1 Yr. Growth % | 8.32 | 2.81 | 53 | -58.3 | -934.94 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -2.89 | -1.53 | 23.44 | -66.54 | -769.82 | |||||
Accounts Receivable, 1 Yr. Growth % | 1.25T | - | - | - | 231.5 | |||||
Inventory, 1 Yr. Growth % | -97.9 | - | - | 260.79 | 291 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 110.85 | 0.43 | 5.1 | -7.41 | 327.43 | |||||
Total Assets, 1 Yr. Growth % | 39.83 | -10.02 | 32.27 | 44.83 | 595.14 | |||||
Tangible Book Value, 1 Yr. Growth % | 42 | -12.32 | 27.39 | 18.06 | -104.55 | |||||
Common Equity, 1 Yr. Growth % | 42 | -12.32 | 27.39 | 20.69 | 378.76 | |||||
Cash From Operations, 1 Yr. Growth % | -3.7 | 15.13 | 57.7 | 31.78 | -445.84 | |||||
Capital Expenditures, 1 Yr. Growth % | 1.17T | -84.61 | 49.21 | -64.64 | 1.85T | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -25.34 | 10.2 | 63.77 | 94.68 | -342.65 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -25.3 | 10.15 | 63.81 | 94.77 | -345.78 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -17.9 | -47.71 | - | 2.48T | - | |||||
Gross Profit, 2 Yr. CAGR % | -31.68 | 33.93 | - | 2.46T | - | |||||
EBITDA, 2 Yr. CAGR % | 18.46 | 6.17 | 29 | -15.03 | 89.14 | |||||
EBITA, 2 Yr. CAGR % | 18.38 | 6.07 | 28.96 | -14.86 | 88.64 | |||||
EBIT, 2 Yr. CAGR % | 18.38 | 6.07 | 28.96 | -14.56 | 80.97 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 31.02 | 16.12 | 28.17 | -22.3 | 87.58 | |||||
Net Income, 2 Yr. CAGR % | 31.02 | 16.12 | 28.17 | -22.3 | 87.58 | |||||
Normalized Net Income, 2 Yr. CAGR % | 17.07 | 5.53 | 25.42 | -20.12 | 86.6 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -35.54 | -2.21 | 10.25 | -35.74 | 49.7 | |||||
Accounts Receivable, 2 Yr. CAGR % | 3.5T | - | - | - | - | |||||
Inventory, 2 Yr. CAGR % | -90.57 | - | 2.55T | - | 275.6 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 332.7 | 45.52 | 2.74 | -1.35 | 98.99 | |||||
Total Assets, 2 Yr. CAGR % | 52.94 | 12.17 | 9.1 | 38.41 | 217.29 | |||||
Tangible Book Value, 2 Yr. CAGR % | 62.96 | 11.58 | 5.69 | 22.64 | -76.83 | |||||
Common Equity, 2 Yr. CAGR % | 62.96 | 11.58 | 5.69 | 24 | 140.38 | |||||
Cash From Operations, 2 Yr. CAGR % | 18.55 | 5.3 | 34.74 | 44.15 | 113.48 | |||||
Capital Expenditures, 2 Yr. CAGR % | 524.29 | 39.55 | -52.08 | -27.37 | 162.77 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 0.07 | -9.29 | 34.34 | 78.56 | 117.35 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 0.74 | -9.29 | 34.33 | 78.62 | 118.79 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -23.7 | -38.65 | - | 510.62 | 1.58T | |||||
Gross Profit, 3 Yr. CAGR % | 8.36 | -11.83 | - | 886.19 | 1.57T | |||||
EBITDA, 3 Yr. CAGR % | 3.12 | 13.41 | 21.74 | -9.12 | 78.91 | |||||
EBITA, 3 Yr. CAGR % | 3.1 | 13.39 | 21.61 | -8.98 | 78.51 | |||||
EBIT, 3 Yr. CAGR % | 3.1 | 13.39 | 21.61 | -8.76 | 73.64 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 1.69 | 21.81 | 28.13 | -14.02 | 76.41 | |||||
Net Income, 3 Yr. CAGR % | 1.69 | 21.81 | 28.13 | -14.02 | 76.41 | |||||
Normalized Net Income, 3 Yr. CAGR % | 3.17 | 12.11 | 19.44 | -13.11 | 74.65 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -20.77 | -25.76 | 5.68 | -25.91 | 40.38 | |||||
Accounts Receivable, 3 Yr. CAGR % | 60.84 | - | - | 944.2 | - | |||||
Inventory, 3 Yr. CAGR % | -80.85 | - | 144.81 | 1.26T | - | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 145.3 | 165.92 | 30.56 | -0.76 | 60.85 | |||||
Total Assets, 3 Yr. CAGR % | 54.14 | 28.15 | 18.51 | 19.9 | 137.03 | |||||
Tangible Book Value, 3 Yr. CAGR % | 133.48 | 32.54 | 16.62 | 9.66 | -59.1 | |||||
Common Equity, 3 Yr. CAGR % | 133.48 | 32.54 | 16.62 | 10.47 | 94.53 | |||||
Cash From Operations, 3 Yr. CAGR % | -3.72 | 17.4 | 20.47 | 33.75 | 92.98 | |||||
Capital Expenditures, 3 Yr. CAGR % | 207.77 | 81.69 | 42.7 | -56.7 | 117.6 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -2.84 | 3.34 | 10.45 | 52.02 | 97.78 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -2.86 | 3.79 | 10.46 | 52.04 | 98.67 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -3.15 | -27.62 | - | 173.66 | 319.75 | |||||
Gross Profit, 5 Yr. CAGR % | -21.69 | -22.05 | - | 239 | 509.67 | |||||
EBITDA, 5 Yr. CAGR % | 3.5 | -1.47 | 12.78 | 1.04 | 45.21 | |||||
EBITA, 5 Yr. CAGR % | 3.52 | -1.44 | 12.75 | 1.11 | 44.96 | |||||
EBIT, 5 Yr. CAGR % | 3.52 | -1.44 | 12.75 | 1.25 | 42.57 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 2.74 | -2.09 | 11.55 | 1.76 | 49.24 | |||||
Net Income, 5 Yr. CAGR % | 2.74 | -2.09 | 11.55 | 1.76 | 49.24 | |||||
Normalized Net Income, 5 Yr. CAGR % | 3.64 | -1.71 | 11.55 | -2.11 | 42.77 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -25.42 | -24.43 | -9.58 | -29.93 | 21.48 | |||||
Accounts Receivable, 5 Yr. CAGR % | 30.44 | - | - | 1.61T | 774.03 | |||||
Inventory, 5 Yr. CAGR % | -55.2 | - | 37.5 | 86.32 | 190.53 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 102.52 | 66.52 | 73.19 | 78.85 | 54.54 | |||||
Total Assets, 5 Yr. CAGR % | 25.77 | 35.76 | 34.24 | 32.16 | 75.72 | |||||
Tangible Book Value, 5 Yr. CAGR % | 28.66 | 50.24 | 70.04 | 28.49 | -38.9 | |||||
Common Equity, 5 Yr. CAGR % | 28.66 | 50.24 | 70.04 | 29.06 | 55.75 | |||||
Cash From Operations, 5 Yr. CAGR % | -1.02 | -3.15 | 10.14 | 27.45 | 51.45 | |||||
Capital Expenditures, 5 Yr. CAGR % | 89.24 | 7.61 | 46.26 | 25.91 | 82.17 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -0.63 | -3.11 | 10.6 | 28.61 | 44.8 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -0.65 | -3.13 | 10.59 | 28.96 | 45.19 |
- Stock Market
- Stocks
- CRMD Stock
- Financials CorMedix Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















